Literature DB >> 18285547

Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells.

Britt E Anderson1, Patricia A Taylor, Jennifer M McNiff, Dhanpat Jain, Anthony J Demetris, Angela Panoskaltsis-Mortari, Ann Ager, Bruce R Blazar, Warren D Shlomchik, Mark J Shlomchik.   

Abstract

Graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality in allogeneic stem cell transplantation. Effector memory T cells (T(EM)) do not cause GVHD but engraft and mount immune responses, including graft-versus-tumor effects. One potential explanation for the inability of T(EM) to cause GVHD is that T(EM) lack CD62L and CCR7, which are instrumental in directing naive T cells (T(N)) to lymph nodes (LN) and Peyer patches (PP), putative sites of GVHD initiation. Thus T(EM) should be relatively excluded from LN and PP, possibly explaining their inability to cause GVHD. We tested this hypothesis using T cells deficient in CD62L or CCR7, transplant recipients lacking PNAd ligands for CD62L, and recipients without LN and PP or LN, PP, and spleen. Surprisingly, CD62L and CCR7 were not required for T(N)-mediated GVHD. Moreover, in multiple strain pairings, GVHD developed in recipients that lacked LN and PP. Mild GVHD could even be induced in mice lacking all major secondary lymphoid tissues (SLT). Conversely, enforced constitutive expression of CD62L on T(EM) did not endow them with the ability to cause GVHD. Taken together, these data argue against the hypothesis that T(EM) fail to induce GVHD because of inefficient trafficking to LN and PP.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18285547      PMCID: PMC2384145          DOI: 10.1182/blood-2007-09-107953

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  56 in total

1.  Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity.

Authors:  Juan E Moyron-Quiroz; Javier Rangel-Moreno; Kim Kusser; Louise Hartson; Frank Sprague; Stephen Goodrich; David L Woodland; Frances E Lund; Troy D Randall
Journal:  Nat Med       Date:  2004-08-15       Impact factor: 53.440

2.  Target antigens determine graft-versus-host disease phenotype.

Authors:  Daniel H Kaplan; Britt E Anderson; Jennifer M McNiff; Dhanpat Jain; Mark J Shlomchik; Warren D Shlomchik
Journal:  J Immunol       Date:  2004-11-01       Impact factor: 5.422

3.  Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease.

Authors:  Benny J Chen; Xiuyu Cui; Gregory D Sempowski; Congxiao Liu; Nelson J Chao
Journal:  Blood       Date:  2003-10-09       Impact factor: 22.113

4.  LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease.

Authors:  Aleksandra Petrovic; Onder Alpdogan; Lucy M Willis; Jeffrey M Eng; Andrew S Greenberg; Barry J Kappel; Chen Liu; George J Murphy; Glenn Heller; Marcel R M van den Brink
Journal:  Blood       Date:  2003-10-16       Impact factor: 22.113

5.  Delaying acute graft-versus-host disease in mouse bone marrow transplantation by treating donor cells with antibodies directed at l-selectin and alpha4-integrin prior to infusion.

Authors:  B Li; J Y New; Y K Tay; E Goh; E H Yap; S H Chan; H Z Hu
Journal:  Scand J Immunol       Date:  2004-05       Impact factor: 3.487

6.  Dendritic cell-activated CD44hiCD8+ T cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activity.

Authors:  Yi Zhang; Gerard Joe; Jiang Zhu; Richard Carroll; Bruce Levine; Elizabeth Hexner; Carl June; Stephen G Emerson
Journal:  Blood       Date:  2004-02-05       Impact factor: 22.113

7.  Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease.

Authors:  Miriam Merad; Petra Hoffmann; Erik Ranheim; Sarah Slaymaker; Markus G Manz; Sergio A Lira; Israel Charo; Donald N Cook; Irving L Weissman; Samuel Strober; Edgar G Engleman
Journal:  Nat Med       Date:  2004-04-18       Impact factor: 53.440

8.  In vivo imaging of graft-versus-host-disease in mice.

Authors:  Angela Panoskaltsis-Mortari; Andrew Price; John R Hermanson; Elizabeth Taras; Chris Lees; Jonathan S Serody; Bruce R Blazar
Journal:  Blood       Date:  2004-01-08       Impact factor: 22.113

9.  Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease.

Authors:  Britt E Anderson; Jennifer M McNiff; Catherine Matte; Ionna Athanasiadis; Warren D Shlomchik; Mark J Shlomchik
Journal:  Blood       Date:  2004-05-18       Impact factor: 22.113

10.  Effect of recent antigen priming on adoptive immune responses. III. Antigen-induced selective recruitment of subsets of recirculating lymphocytes reactive to H-2 determinants.

Authors:  J Sprent; J F Miller
Journal:  J Exp Med       Date:  1976-03-01       Impact factor: 14.307

View more
  41 in total

1.  Recipient B cells are not required for graft-versus-host disease induction.

Authors:  Catherine Matte-Martone; Xiajian Wang; Britt Anderson; Dhanpat Jain; Anthony J Demetris; Jennifer McNiff; Mark J Shlomchik; Warren D Shlomchik
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-23       Impact factor: 5.742

2.  Kinetics of lymphocyte reconstitution after allogeneic bone marrow transplantation: markers of graft-versus-host disease.

Authors:  Severin Zinöcker; Lisbet Sviland; Ralf Dressel; Bent Rolstad
Journal:  J Leukoc Biol       Date:  2011-04-15       Impact factor: 4.962

3.  Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease.

Authors:  Yi Zhang; Ashley R Sandy; Jina Wang; Vedran Radojcic; Gloria T Shan; Ivy T Tran; Ann Friedman; Koji Kato; Shan He; Shuaiying Cui; Elizabeth Hexner; Dale M Frank; Stephen G Emerson; Warren S Pear; Ivan Maillard
Journal:  Blood       Date:  2010-09-24       Impact factor: 22.113

Review 4.  GVHD: a continuing barrier to the safety of allogeneic transplantation.

Authors:  Pavan Reddy; Mukta Arora; Martin Guimond; Crystal L Mackall
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

5.  Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation.

Authors:  Yi-Bin Chen; Haesook T Kim; Sean McDonough; Robert D Odze; Xiaopan Yao; Suzan Lazo-Kallanian; Thomas R Spitzer; Robert Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Biol Blood Marrow Transplant       Date:  2009-07-08       Impact factor: 5.742

6.  Altered T-cell entry and egress in the absence of Coronin 1A attenuates murine acute graft versus host disease.

Authors:  LeShara M Fulton; Nicholas A Taylor; James M Coghill; Michelle L West; Niko Föger; James E Bear; Albert S Baldwin; Angela Panoskaltsis-Mortari; Jonathan S Serody
Journal:  Eur J Immunol       Date:  2014-06       Impact factor: 5.532

7.  Allospecific CD4(+) effector memory T cells do not induce graft-versus-host disease in mice.

Authors:  Ping Zhang; Jieying Wu; Divino Deoliveira; Nelson J Chao; Benny J Chen
Journal:  Biol Blood Marrow Transplant       Date:  2012-07-15       Impact factor: 5.742

8.  In vivo dynamics of T cells and their interactions with dendritic cells in mouse cutaneous graft-versus-host disease.

Authors:  Sarah Morin-Zorman; Christian Wysocki; Jieqing Zhu; Hongmei Li; Sylvain Zorman; Catherine Matte-Martone; Edwina Kisanga; Jennifer McNiff; Dhanpat Jain; David Gonzalez; David M Rothstein; Fadi G Lakkis; Ann Haberman; Warren D Shlomchik
Journal:  Blood Adv       Date:  2019-07-23

9.  PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease.

Authors:  Kathryn W Juchem; Faruk Sacirbegovic; Cuiling Zhang; Arlene H Sharpe; Kerry Russell; Jennifer M McNiff; Anthony J Demetris; Mark J Shlomchik; Warren D Shlomchik
Journal:  J Immunol       Date:  2017-12-06       Impact factor: 5.422

10.  Risk stratification of organ-specific GVHD can be improved by single-nucleotide polymorphism-based risk models.

Authors:  D Kim; H-H Won; S Su; L Cheng; W Xu; N Hamad; J Uhm; V Gupta; J Kuruvilla; H A Messner; J H Lipton
Journal:  Bone Marrow Transplant       Date:  2014-03-03       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.